Skip to main content


Firm News

Mayer Brown represents Adaptimmune on two offerings raising over $100 million

5 April 2017
Mayer Brown announced today that it represented Adaptimmune Therapeutics, a Nasdaq-listed cancer immunotherapy company, on a $62 million public equity offering. The offering was led by Citigroup, Cowen and Company and Leerink Partners and was done as a confidentially marketed public offering. Following that offering, Adaptimmune did a registered direct offering and raised an additional $42 million.

The Mayer Brown team was led by New York-based Corporate & Securities partner David Bakst and included lawyers from the firm’s Corporate & Securities, Employment & Benefits, Intellectual Property, Litigation & Dispute Resolution and Tax Transactions & Consulting practices in Chicago, London, New York, São Paulo and Washington DC.
The Build a Report feature requires the use of cookies to function properly. Cookies are small text files that are placed on your computer by websites that you visit. They are widely used in order to make websites work, or work more efficiently. If you do not accept cookies, this function will not work. For more information please see our Privacy Policy

You have no pages selected. Please select pages to email then resubmit.